I was long Ziopharm Oncology (NASDAQ:ZIOP) from sometime in 2009 until around April 2013. I believed palifosfamide would improve progression free survival in sarcoma patients, the drug would get approved, and ZIOP could use that revenue to bankroll a robust pipeline of game-changing oncology therapeutics with a little help from Intrexon (NYSE:XON). After the palifosfamide failure, like many, I threw in the towel. I just couldn't wait around another four years while Ziopharm again transformed itself into a "late-stage" oncology company. Recently, I wrote an article on CorMedix (NYSEMKT:CRMD), contrasting the market cap of CRMD with that of ZIOP. In this article I was generally critical of ZIOP without getting into specifics and received...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|